美股異動 | 腦再生科技盤前跌超10%,此前2個交易日累漲近400%
連續大漲的腦再生科技(RGC.US)盤前跌超10%,該股此前兩個交易日累漲近400%,最高達到83.6美元。消息上,受到資本追捧的腦再生科技,是一家早期中藥生物科學公司,主營業務主要是:開發三種液態標準化中藥配方,用於治療輕度、中度和重度的ADHD(注意缺陷多動障礙)和ASD(自閉症譜系障礙)患者。2014年創立於香港銅鑼灣,腦再生科技目前主要運營及資產都在香港,員工人數只有12人。在此前5月9日,腦再生科技宣佈其新一代神經調控芯片通過FDA臨牀試驗審批,將與全球頂尖醫療機構梅奧診所合作,開展帕金森病治療研究。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.